Cyclerion shares surge 32.22% after-hours as insiders buy $525k in stock, signaling confidence.

Cyclerion Therapeutics surged 32.22% in after-hours trading following a significant insider buying activity. Insiders, including Director Peter Hecht, purchased $525,000 worth of shares over the past year, with the largest single transaction involving $500,000 at $2.75 per share—well above the current price of $1.80. This activity, combined with no insider sales in the last year and 23% insider ownership, signals strong confidence in the company’s long-term prospects. The purchases at higher prices suggest insiders viewed the stock as undervalued, reinforcing a bullish sentiment. While the article notes some risks, the immediate price reaction aligns with the positive signal from insider transactions, which are often interpreted as a vote of confidence in management’s strategic direction.